The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiologists and the American Society of ExtraCorporeal Technology have released guidelines for the use of blood thinners during cardiac surgery. The protocols were published in the Annals of Thoracic Surgery, Anesthesia & Analgesia and the Journal of ExtraCorporeal Technology.
Clinical laboratories face some challenges when measuring microRNA biomarkers because test results can be hard to interpret, miRNAs contain little information and most are expressed widely in a noncell-specific manner. New developments such as amplification-free technologies or use of the miRNA as the primer may ease adoption in laboratories.
A study in the journal Proceedings of the National Academy of Sciences found the incidence of HIV in the Ukraine has risen by 15% to 54%, particularly in areas affected by military conflict. About half of people with HIV are unaware of their status, researcher Tetyana Vasylyeva said.
The Senate has reached an agreement to end the government shutdown after Senate Majority Leader Mitch McConnell, R-Ky., promised to open debate on immigration. Senators were set to vote on a short-term spending bill that provides funding through Feb. 8, with the House expected to later approve the measure and send it to the president.
A Series A funding round brought in $58 million for Pandion Therapeutics. The company is developing bispecific antibodies as potential treatments for autoimmune liver diseases and inflammatory bowel disease.
A robot-aided study in the journal Scientific Reports found that triclosan inhibits not just enoyl reductase but also the enzyme dihydrofolate reductase in malarial parasites. The robot, called Eve, was developed to use artificial intelligence and machine learning to run faster laboratory experiments.
The Zimbabwe Healthcare Fund will receive $502 million over three years from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Most of the funding will go toward providing HIV prevention, care and support.
GC Pharma of South Korea has been granted approval by the country's Ministry of Food and Drug Safety to proceed with a Phase II/III clinical study of its Hepabig-gene recombinant hepatitis B immunoglobulin. The multi-center study will compare Hepabig-gene with current treatments for liver transplant recipients with hepatitis B.
- Page 1